Valuation: Alto Neuroscience, Inc.

Market Cap 1.11B 964M 900M 826M 1.55B 106B 1.58B 10.56B 4.15B 53.16B 4.18B 4.09B 176B P/E 2026 *
-9.4x
P/E 2027 * -8.7x
Enterprise Value 930M 804M 751M 689M 1.3B 88.49B 1.32B 8.81B 3.46B 44.35B 3.49B 3.42B 147B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.89%
Yield 2026 *
-
Yield 2027 * -
1 day+0.70%
1 week+5.91%
Current month+5.91%
1 month+11.56%
3 months+19.11%
6 months+88.37%
Current year+61.07%
1 week 25.8
Extreme 25.8
29.49
1 month 24.81
Extreme 24.81
29.49
Current year 13.91
Extreme 13.9121
29.49
1 year 3.02
Extreme 3.02
29.49
3 years 1.6
Extreme 1.6
29.49
5 years 1.6
Extreme 1.6
29.49
10 years 1.6
Extreme 1.6
29.49
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 44 2019-12-31
Chief Executive Officer 50 2019-03-24
Director of Finance/CFO 38 2022-10-31
Director TitleAgeSince
Chairman 50 2019-03-24
Director/Board Member 47 2022-03-31
Director/Board Member 67 2023-10-17
Date Insider Type Main position Quantity % Market Cap.
5/14/26 Don

Chief Executive Officer

-400,000 1.2521%
5/12/26 Free

Director

10,958 0.0343%
3/1/26 Tax

Chief Executive Officer

6,227 0.0200%
Change 5-day change 1-year change 3-year change Capi.($)
+0.70%+5.91%+836.93% - 1.11B
+0.99%+1.78%+4.07%+16.73% 49.47B
+3.71%+9.40%+486.98%+592.14% 43.61B
+5.60%+10.21%+16.76%+85.72% 39.6B
+2.70%+1.57%+33.39%+8.85% 39.29B
+2.21%+6.75%+21.31%+53.37% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+37.75%+126.84% 16.49B
-0.11%+2.41%+6.24%+18.87% 14.01B
+0.75%+15.04%+78.59%+30.30% 12.77B
Average +1.98%+6.28%+169.11%+116.60% 26.56B
Weighted average by Cap. +2.53%+6.10%+107.54%+140.79%

Financials

2026 *2027 *
Net sales - -
Net income -106M -91.83M -85.76M -78.67M -148M -10.1B -150M -1.01B -395M -5.06B -399M -390M -16.74B -130M -112M -105M -96.04M -181M -12.33B -184M -1.23B -482M -6.18B -487M -476M -20.44B
Net Debt -185M -160M -149M -137M -257M -17.57B -261M -1.75B -687M -8.81B -693M -678M -29.11B -271M -234M -219M -201M -377M -25.76B -383M -2.57B -1.01B -12.91B -1.02B -994M -42.69B
Logo Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Employees
68
Date Price Change Volume
26-08-07 US$28.67 +0.70% 336,434
26-08-06 US$28.47 +1.57% 421,152
26-08-05 US$28.03 -0.71% 248,885
26-08-04 US$28.23 +3.52% 555,437
26-08-03 US$27.27 +0.74% 409,065
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
28.67USD
Average target price
35.64USD
Spread / Average Target
+24.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANRO Stock